Mineralys Therapeutics

Mineralys

This biopharmaceutical company develops aldosterone synthase inhibitors to treat patients with uncontrolled hypertension and related cardio-renal-metabolic diseases.

CINC

This company develops biopharmaceutical treatments for cardio-renal diseases, primarily for patients with hypertension and chronic kidney disease.

Ardian

This company develops medical devices for catheter-based renal denervation to treat hypertension in patients with high blood pressure.

Chinook Therapeutics

This biopharmaceutical company develops precision medicines for patients with rare and severe chronic kidney diseases.

Pathalys Pharma

This biopharmaceutical company develops treatments for secondary hyperparathyroidism in patients with end-stage kidney disease undergoing dialysis.

Cerenis Therapeutics Holding SA

This biopharmaceutical company develops high-density lipoprotein therapies to treat patients with cardiovascular and metabolic diseases, as well as renal and oncology conditions.

SoniVie

SoniVie develops ultrasound-based intravascular denervation systems to treat patients with hypertensive disorders, including resistant hypertension and pulmonary arterial hypertension.

Revier Therapeutics

This company develops orally available small molecules targeting class IIa histone deacetylases to treat patients with heart failure and atherosclerotic cardiovascular diseases.